Resilience

Overview

Resilience is a United States-based company founded in 2020, operating within the manufacturing sector, specifically focusing on pharmaceuticals and biomanufacturing. With a workforce of 1,001 to 5,000 employees and reported revenues of approximately $568.8 million, Resilience specializes in the development and manufacturing of complex drug products, including vaccines that utilize aluminum adjuvants. The company emphasizes its capabilities in technology transfer, process scale-up, and the production of alum-containing vaccines, addressing challenges such as filterability and packaging through advanced manufacturing environments and specialized equipment. Resilience has published technical reports and white papers that detail its methodologies and insights into vaccine development, including the role of aluminum salts in enhancing vaccine efficacy. Their documentation reflects a commitment to supporting vaccine discovery and manufacturing processes, leveraging their expertise in biomanufacturing to facilitate partnerships with Contract Development and Manufacturing Organizations (CDMOs) in the pharmaceutical industry.

Industry